Surgical Myectomy for Hypertrophic Obstructive Cardiomyopathy  
The Cut That Heals  
Lynne K. Williams, MB BCh, PhD; Harry Rakowski, MD

Hypertrophic cardiomyopathy (HCM) has been one of the most interesting and controversial disorders in cardiovascular medicine. Although initial descriptions of the pathology of HCM were published over a century ago, it was not until the surgical and pathological observations of Brock and Teare, respectively, that this cardiac entity came to attention in the modern era. HCM is a primary disorder of the myocardium characterized by myocyte hypertrophy and fiber disarray, myocardial fibrosis, and abnormal coronary intramural microvasculature. Although HCM is characterized by tremendous diversity in terms of phenotypic expression, genetic substrate, and clinical presentation, left ventricular outflow tract (LVOT) obstruction is an integral component of the disease, occurring in up to 70% of patients either at rest or with provocation.1

External compression of the LVOT, whether due to left ventricle (LV) as opposed to true mechanical impediment left ventricle (LV) as opposed to true mechanical impediment, is driven by Venturi and drag forces of the anterior mitral valve leaflet. Echocardiographic and cardiac magnetic resonance studies have documented that reduction in the LVOT cross-sectional area is attributable to morphological features such as narrowing of the LVOT by septal hypertrophy, intrinsic abnormalities of the mitral valve leaflets, anterior displacement of the mitral apparatus, and anterior malposition of the papillary muscles, either alone or in combination. Rapid LV ejection through a narrowed outflow tract results in the anterior mitral leaflet being subjected to Venturi and drag forces distal to the site of coaptation with the posterior mitral leaflet. These forces draw and then continue to push the anterior leaflet toward the septum, resulting in the development of a sharp anterior and superior angulation of the leaflet and mitral leaflet-septal contact in early to midsystole (systolic anterior motion). The resulting distortion of the mitral valve leaflets results in malcoaptation and an interleaflet gap, giving rise to the posteriorly directed jet of mitral regurgitation that is typically seen in most patients with LVOT obstruction (Figure).

Outflow tract obstruction imposes a hemodynamic load on the LV, resulting in a complex interplay of diastolic dysfunction, elevated LV end-diastolic pressure, mitral regurgitation, and myocardial ischemia. Clinically, LVOT obstruction causes symptoms of dyspnea, ischemic chest pain, presyncope, or syncope with exertion. Obstruction is typically dynamic in nature, dependent on inotropic and chronotropic state, loading conditions, and systemic vascular resistance. Although resting LVOT obstruction (defined as a peak instantaneous LVOT gradient ≥30 mmHg) is present in ≈25% to 30% of patients with HCM, another third or more have evidence of latent LVOT obstruction (<30 mmHg at rest and ≥30 mmHg with provocation) with physiological maneuvers such as the Valsalva maneuver or exercise testing.1

The importance of identifying LVOT obstruction lies in its adverse impact on morbidity and mortality. In a large multicenter study, resting LVOT obstruction was associated not only with a higher likelihood of death as a result of HCM, but also with progression to New York Heart Association class III or IV symptoms or death as a result of heart failure or stroke.5

Medical Therapy for Symptomatic Obstructive HCM

Although some individuals with LVOT gradients ≥50 mmHg are asymptomatic, most present with symptoms necessitating therapy. β-Blockers remain the cornerstone of therapy and, via their negative inotropic and chronotropic effect, reduce obstruction and improve diastolic filling. In patients intolerant of β-blockers, verapamil may result in symptomatic improvement. However, calcium channel blockers should be used cautiously in patients with severe LVOT obstruction and elevated pulmonary artery wedge pressures because of the risk of precipitating pulmonary edema. Since the first introduction of disopyramide by investigators in our institution,6 numerous reports have attested to its safety and efficacy as a second-line agent in patients resistant to therapy with β-blockers or calcium channel blockers.7 The addition of disopyramide in

DOI: 10.1161/CIRCULATIONAHA.113.003953

Correspondence to Harry Rakowski, MD, Division of Cardiology, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the Division of Cardiology, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.

Article see p 209
these patients, via its negative inotropic effect, may result in significant symptomatic improvement, as demonstrated in large series from Toronto and New York. Disopyramide is used less frequently in the United States than in Canada and Europe, in part, because of guideline recommendations to commence disopyramide in an inpatient setting with ECG monitoring for QT prolongation. However, in our practice, we have commenced disopyramide therapy in several hundred outpatients without any apparent major cardiac events or deaths. Several studies have demonstrated that approximately two-thirds of patients can be managed with medical therapy with amelioration of symptoms and >50% reduction in the LVOT gradient. In addition, Ball and colleagues have demonstrated that the long-term survival of patients treated conservatively with medical therapy is much better than previously thought. In their large cohort of 649 patients, they showed that those patients who demonstrate both a significant improvement in symptoms and reduction in resting LVOT gradient have a similar overall and HCM-related survival to patients treated by an invasive septal reduction strategy.

**Interventional Therapy for Obstructive HCM**

Despite the efficacy and safety of medical therapy, a significant proportion of patients require interventional strategies for relief of LVOT obstruction. Given the potential complications of invasive therapies, it is important that patients fulfill clinical, anatomic, and hemodynamic criteria to determine suitability for a particular procedure. The American College of Cardiology Foundation/American Heart Association 2011 guidelines recommend that septal reduction therapy only be performed by experienced operators in the context of a comprehensive clinical HCM program, for patients with severe symptoms refractory to maximally tolerated medical therapy with a resting or provokable LVOT gradient ≥50 mm Hg, and septal hypertrophy of sufficient thickness to perform the procedure safely and effectively.

Alcohol septal ablation (ASA), when performed in experienced centers, provides a suitable alternative for those patients of advanced age or with significant comorbidities that increase surgical risk, or to avoid surgery. Infarction of the territory supplied by the obliterated septal perforator(s) leads to regression of subaortic hypertrophy with scar formation over a 6- to 12-month period. Myectomy surgery is generally preferred when septal hypertrophy is excessive, or concomitant surgery on the coronary arteries or mitral valve apparatus is required.

Dual-chamber pacing, although a potential therapeutic option, has shown only a modest benefit in randomized, controlled trials. Its primary use is in patients >65 years of age or those who have an independent indication for pacemaker implantation (or implantable cardioverter defibrillator) or an unacceptably high risk for surgical myectomy or alcohol septal ablation.

**Surgical Myectomy for Obstructive HCM**

Brock’s initial report of muscular hypertrophy of the LVOT led to the concept that surgical division or myotomy of septal muscle bundles would lead to relief of obstruction via interruption of the sphincter-like muscular contraction ring.
Cleland and colleagues first performed a myectomy in November 1958 via the transapical approach in London, England. In early case reports, a reduction in LVOT gradients was observed in most patients, but in-hospital mortality was high, and obstruction persisted in some patients. Thereafter, surgical intervention (first in the form of myotomy and subsequently myectomy) was pioneered by Morrow (National Institutes of Health), Kirklin (Mayo Clinic), and Bigelow and Williams (Toronto General Hospital). The classic myectomy (Morrow operation or trough myectomy) involved resection of only a small amount of muscle from the proximal interventricular septum, thereby increasing the cross-sectional area of the LVOT. More recently, surgeons have used an extended myectomy, whereby muscular resection is wider and extends more distally beyond the point of systolic anterior motion-septal contact toward the base of the anterolateral papillary muscle, allowing more complete abolition of systolic anterior motion and LVOT obstruction. Newer surgical approaches have been described that include resection of septal muscle in addition to mitral valve plication and papillary muscle manipulation.

In this issue of Circulation, Desai et al describe a consecutive 11-year experience of 699 patients who underwent septal myectomy at the Cleveland Clinic for obstructive HCM between January 1997 and December 2007. This series is similar to reports from other HCM centers of excellence (both in terms of patient population and results), with the exception of the exclusion of patients labeled as having hypertensive heart disease and concomitant LVOT obstruction and patients with LV systolic dysfunction. In addition, the preoperative use of disopyramide in the current series was only 7%, a rate significantly lower than our experience in Toronto, but in keeping with the prevalence of disopyramide use in other centers in the United States. In this series concomitant surgical procedures included mitral valve repair/replacement (23%), coronary bypass grafting (9%), combined mitral and coronary surgery (3%), surgical maze or pulmonary vein isolation (11%), and left atrial appendage ligation/exclusion (14%). Concomitant mitral surgery was more common in patients with a septal thickness <2 cm (41%) than in those with a septal thickness ≥2 cm (25%). Over a mean follow-up period of 6.2 years, the authors demonstrate a low event rate (using a composite end point of all death, appropriate automatic implantable cardioverter defibrillator (AICD) discharges, resuscitated sudden death, documented stroke, and onset of congestive heart failure requiring inpatient hospitalization) at 30 days (0.7%) and at 1 year (2.8%). In addition, the hard event rate (death, appropriate AICD discharge, or revival from sudden death) was also low at 30 days (0%) and 1 year (1.5%). An excellent hemodynamic and symptomatic response to surgery is reported, with postoperative resting and provokable LVOT gradients of <30 mm Hg in 98% of patients and <50 mm Hg in 84%, respectively, in association with New York Heart Association class I or II symptoms in 96% of cases. Non-sustained ventricular tachycardia was noted in 71 patients during follow-up, with sustained ventricular tachycardia in a further 3 patients. Redo surgery was performed in 3.4% of cases for residual LVOT obstruction (80% of reoperations were mitral valve replacement). After multivariate analysis, predictors of poor outcome after myectomy included advanced age and persistence of postoperative atrial fibrillation, whereas concomitant surgical procedures predicted composite events only on univariate analysis. Increasing age has previously been shown to be related to outcome in several surgical series, including those from Toronto and New York. Similarly, the need for concomitant surgical procedures as opposed to isolated myectomy is a well-established risk factor for adverse outcomes. Woo et al have previously demonstrated an association between preoperative atrial fibrillation and poor outcome, but this is the first study to relate residual postoperative atrial fibrillation with both composite and hard events.

The current article adds to a substantial body of literature demonstrating the efficacy of surgical myectomy, which can be performed in experienced high-volume centers with not only low morbidity and mortality, but also excellent long-term symptomatic improvement, excellent hemodynamics, and low sudden death rates. With greater expertise in surgical technique, there has been a clear reduction in operative mortality and improved long-term survival since the initial published series in the 1980s and 1990s, as demonstrated in the Table. In addition, concomitant surgical procedures are performed more frequently, likely because of operating on older patients with significant comorbidities. Although ASA has emerged as an effective invasive approach for the relief of LVOT obstruction, surgery offers the advantage of immediate and greater reductions in LVOT gradients, with low perioperative mortality and morbidity and excellent long-term survival. Although concern remains over the long-term arrhythmic risk associated with the creation of an area of myocardial infarction after ASA in patients already at risk of life-threatening arrhythmias, many reports have suggested that these concerns are unfounded. However, several series have raised concerns regarding long-term outcome. Ten Cate et al demonstrated an annual event rate (cardiac death, aborted cardiac arrest, and appropriate AICD discharge) of 4.4% following ASA. Similarly, data from the Massachusetts General Hospital suggests a 5% annual event rate for ventricular tachycardia/ventricular fibrillation after ASA. These event rates clearly exceed those of surgical myectomy, although differences exist between patient groups in terms of age and comorbidities that limit direct comparison. However, the long-term survival after ASA remains to be determined, given the length of follow-up in most studies is relatively short in comparison with the gold standard of surgical myectomy.

**Does Myectomy Confer Additional Benefits?**

Although several studies have demonstrated the safety and efficacy of medical therapy in patients with obstructive HCM, with a overall and HCM-related survival similar to those patients treated by an invasive septal reduction strategy, there remains a clear benefit for myectomy in those patients who remain in New York Heart Association class III or IV despite optimal medical therapy.

Left atrial dilatation, a marker of adverse cardiovascular outcomes including atrial fibrillation (AF), stroke, sudden death, and heart failure–related mortality, has been shown to be subject to beneficial reverse remodeling after myectomy, with a significant reduction in left atrial volume index. Incidence of AF after myectomy (excluding the initial period) is not widely

---

**Circulation** (2018) 137;1799-1808

**Funding:** This work was supported by the National Heart, Lung, and Blood Institute (HL126075) and the National Institutes of Health (HL126075). A.T.C. is supported by a National Institutes of Health K08 Award (K08HL130897). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Disclosures:** The authors report no conflicts of interest.

**References:**


Myectomy itself appears to alter the natural history of HCM, diac death or appropriate AICD discharges after myectomy. In fact, many series have reported a low risk of sudden carmia owing to the lack of creation of intramyocardial scarring. ≈ 10%, myectomy carries no increased risk of arrhythto be ASA, which has been demonstrated in short-term follow-up.

Invasive procedures for HCM, these should be performed in centers with adequate procedural volumes to ensure good early and long-term results. Although controversy still exists as to what intervention is best, Desai et al have provided important additional evidence highlighting that surgical myectomy remains the gold standard with which other procedures need to be compared. The results for myectomy are unmatched for early efficacy, low procedural mortality and morbidity, and the ability to perform concomitant coronary and valve surgery that is required in about one-third of referred patients. Desai et al have further confirmed not only the sustained excellent long-term benefit of surgical myectomy, but also the risks of post-myectomy AF, which remains a major management challenge. Surgical myectomy is truly the cut that heals, and the achievable outstanding early and late outcomes should be an impetus to create more centers of surgical excellence around the world.

**Conclusion and Summary**

Patients with symptomatic obstructive HCM in whom medical therapy has failed require an invasive interventional therapy to restore them to long-term health. Regardless of the procedure chosen, operator and institutional experience are crucial to successful outcomes and low periprocedural morbidity and mortality. Given the substantial learning curve associated with invasive procedures for HCM, these should be performed in centers with adequate procedural volumes to ensure good early and long-term results. Although controversy still exists as to what intervention is best, Desai et al have provided important additional evidence highlighting that surgical myectomy remains the gold standard with which other procedures need to be compared. The results for myectomy are unmatched for early efficacy, low procedural mortality and morbidity, and the ability to perform concomitant coronary and valve surgery that is required in about one-third of referred patients. Desai et al have further confirmed not only the sustained excellent long-term benefit of surgical myectomy, but also the risks of post-myectomy AF, which remains a major management challenge. Surgical myectomy is truly the cut that heals, and the achievable outstanding early and late outcomes should be an impetus to create more centers of surgical excellence around the world.

**Table. Published Surgical Myectomy Series**

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Patients Enrolled</th>
<th>Concomitant Procedures, %</th>
<th>Follow-Up</th>
<th>Pacemaker Implantation, %</th>
<th>30-day Mortality, %</th>
<th>5-y Survival, %</th>
<th>10-y Survival, %</th>
<th>NYHA I or II, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohr et al</td>
<td>1989</td>
<td>115</td>
<td>17.4</td>
<td>5.1 y</td>
<td>N/A</td>
<td>5.2</td>
<td>84</td>
<td>73</td>
<td>N/A</td>
</tr>
<tr>
<td>Seiler et al</td>
<td>1991</td>
<td>79</td>
<td>N/A</td>
<td>9.4 y</td>
<td>N/A</td>
<td>1.3</td>
<td>96</td>
<td>84</td>
<td>N/A</td>
</tr>
<tr>
<td>Schulte et al</td>
<td>1993</td>
<td>364</td>
<td>25.3</td>
<td>8.2 y</td>
<td>N/A</td>
<td>2.9</td>
<td>92</td>
<td>88</td>
<td>N/A</td>
</tr>
<tr>
<td>Heric et al</td>
<td>1995</td>
<td>178</td>
<td>44.9</td>
<td>44 mo</td>
<td>10</td>
<td>6</td>
<td>86</td>
<td>70</td>
<td>95</td>
</tr>
<tr>
<td>Robbins and Inno</td>
<td>1996</td>
<td>158</td>
<td>17.1</td>
<td>6.1 y</td>
<td>2.5</td>
<td>3.2</td>
<td>85.4</td>
<td>71.5</td>
<td>94</td>
</tr>
<tr>
<td>Schönbeck et al</td>
<td>1998</td>
<td>110</td>
<td>21</td>
<td>11.7 y</td>
<td>4.5</td>
<td>3.6</td>
<td>93</td>
<td>80</td>
<td>91</td>
</tr>
<tr>
<td>Woo et al</td>
<td>2005</td>
<td>388</td>
<td>28</td>
<td>7.7 y</td>
<td>6</td>
<td>1.5</td>
<td>95</td>
<td>83</td>
<td>83</td>
</tr>
<tr>
<td>Ommen et al</td>
<td>2005</td>
<td>289</td>
<td>N/A</td>
<td>6.2 y</td>
<td>1</td>
<td>0.8</td>
<td>96</td>
<td>83</td>
<td>94</td>
</tr>
<tr>
<td>Iacovoni et al</td>
<td>2011</td>
<td>124</td>
<td>25</td>
<td>20.3 mo</td>
<td>3.2</td>
<td>0.8</td>
<td>96.7</td>
<td>88.8</td>
<td>96</td>
</tr>
<tr>
<td>Ross et al</td>
<td>2011</td>
<td>132</td>
<td>43</td>
<td>4.2 y</td>
<td>3.8</td>
<td>0</td>
<td>99</td>
<td>92</td>
<td>N/A</td>
</tr>
<tr>
<td>Wang et al</td>
<td>2013</td>
<td>93</td>
<td>39.8</td>
<td>10.7 mo</td>
<td>3.2</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>100</td>
</tr>
<tr>
<td>Desai et al</td>
<td>2013</td>
<td>699</td>
<td>35</td>
<td>6.2 y</td>
<td>7</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
<td>96</td>
</tr>
</tbody>
</table>

N/A indicates not available; and NYHA, New York Heart Association.

**References**


Key Words: Editorials ■ cardiomyopathy, hypertrophic ■ left ventricular outflow obstruction